Objective: The present study was designed to determine the effects of chronic reduction in uterine blood flow (UBF) on umbilical blood flow (UmbBF) and fetal cardiovascular hemodynamics and oxygenation.
Study Design: Sixteen sheep with singleton pregnancies were instrumented on gestational day (GD) 110; an externally adjustable vascular occluder was placed on the common internal iliac artery. UBF in control animals rose from 867 +/- 61 mL/min on GD 115 to 1520 +/- 158 mL/min (n = 8) on GD 138, whereas UBF in restricted animals was maintained at 750 +/- 50 mL/min (n = 8).
Results: UmbBF in control animals increased from 472 +/- 25 mL/min to 744 +/- 58 mL/min over the study period from GD 115 to GD 138. This was associated with normal gestational increases in fetal arterial pressure and significant reductions in calculated umbilical vascular resistance. Although restricted animals initially had a similar UmbBF on GD 115, UmbBF rose only to 545 +/- 43 mL/min over the study period (control vs restricted, P <.008). Although fetal arterial pressure showed normal gestational changes, umbilical vascular resistance failed to decrease over gestation in restricted animals as it did in control animals. Fetal heart rate and oxygenation showed normal changes in both groups.
Conclusion: Chronic reduction in UBF prevents umbilical vascular resistance from undergoing normal gestational decreases, leading to significantly lower UmbBF. This altered umbilical perfusion pattern would be expected to significantly affect fetal delivery of oxygen and nutrients and ultimately fetal growth.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1067/mob.2002.122849 | DOI Listing |
Background: Neurofilament Light Chain (NfL) is a blood biomarker of axonal injury and neurodegeneration that can be used in a variety of neurological disorders. Despite the potential clinical use of plasma NfL across multiple neurological disorders, there is increasing evidence that underlying comorbidities such as renal impairment associated with chronic kidney disease (CKD) and cardiovascular diseases can increase NfL concentrations. The objective of this study was to determine the relationship between plasma NfL concentrations and renal function (CKD staging) in individuals without known neurological conditions.
View Article and Find Full Text PDFInt J Surg
January 2025
Department of Urology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Background: Giant hydronephrosis as an rare condition is often caused by chronic ureteral obstruction. Nephroplication is a crucial procedure to improve urinary drainage in the kidney-sparing surgery for patients with giant hydronephrosis. However, traditional nephroplication via suturing kidney has technical difficulty and many potential risks.
View Article and Find Full Text PDFBackground: Chronic kidney disease (CKD) has been associated with increased plasma phosphorylated Tau217 (pTau217) concentrations, potentially confounding its utility in the evaluation of Alzheimer's disease (AD). We assessed the association of estimated glomerular filtration rate (eGFR) with plasma pTau217 concentrations measured by various assays.
Method: We included 195 participants from the Mayo Clinic Study of Aging or the Alzheimer's Disease Research Center with diagnoses of cognitively unimpaired (n=114), mild cognitive impairment (n=70), and AD dementia (n=11).
Background: Prescription for inappropriate drugs can be dangerous to very old people, due to the increased risk of adverse drug reactions.
Case Report: We report the consequences of inappropriate prescriptions in a 99-year-old woman. She had a clinical history of vascular dementia, diabetes, hypothyroidism, heart failure, osteoarthritis, chronic renal failure, and hypoacusia, and was admitted to our attention for asthenia and loss of appetite.
Clin Kidney J
January 2025
MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
Background: The serum calcification propensity test (or T50 test) might become a standard tool for the assessment of vascular calcification risk and T50 might be a valuable biomarker in clinical trials of treatments intended to slow the progression of vascular calcification. Literature data suggest that non-calcium-containing phosphate binders can influence T50 in chronic dialysed patients. However, it is not clear whether similar interventions are effective in patients at earlier stages of chronic kidney disease (CKD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!